TP53 and hepatocellular carcinoma: In addition, MTS derivatives 1 and 3 blocked the G1/S phase of the cell cycle by increasing the intracellular reactive oxygen species levels, up-regulating p38 MAPK activity, stabilizing p53, and activating p21 transcription to play a role in anti-hepatoma activity, suggesting that these two MTS derivatives can be used as potential novel hepatocellular carcinoma inhibitors [17].